Attovia Therapeutics to Participate in Two Upcoming Investor Conferences in September

SAN CARLOS, Calif., Sept. 03, 2026 /CourierPR/ -- Attovia Therapeutics, a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences in September 2026, providing insights into its pipeline of next-generation biotherapeutics for immune-mediated diseases.

On September 10, 2026, company management will attend the Citi’s 2026 Biopharma Back to School Conference, where they will engage in one-on-one meetings with investors. The second conference, the Morgan Stanley 24th Annual Global Healthcare Conference, will take place on September 16, 2026. Here, Attovia’s executives will participate in a fireside chat, scheduled from 10:00 AM to 10:35 AM Eastern Standard Time. A webcast of this session will be available on Attovia’s website, with a replay accessible for approximately 90 days following the event.

Attovia Therapeutics is developing innovative biotherapeutics for conditions with high unmet medical needs. The company’s ATTOBODY™ platform, an evolution-driven, high-throughput process, enables the rapid discovery and creation of diverse product candidates. Among Attovia’s lead programs is ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases. ATTO-2306, a bispecific antibody targeting both IL-31 and IL-13, is currently in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases. Additionally, ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7, is also in IND-enabling studies for inflammatory bowel disease.

Attovia’s portfolio also includes highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics, highlighting the company’s commitment to advancing treatments for immune-mediated diseases.